Previously announced merger of the Rochester, New York-based vaccine manufacturer with American Cyanamid is effective as of Nov. 14, following vote of approval by Praxis shareholders. . . . Xoma: Berkeley, California-based monoclonal antibody R&D firm completes previously-announced stock swap merger with another monoclonal antibody R&D firm, Ingene, which becomes a wholly owned subsidiary of Xoma. . . .
You may also be interested in...
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.